Original Article
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
N Engl J Med 1994; 331:904-909October 6, 1994
- Abstract
Background
Cabergoline is a long-acting dopamine-agonist drug that suppresses prolactin secretion and restores gonadal function in women with hyperprolactinemic amenorrhea. We designed a study to compare its safety and efficacy with those of bromocriptine, which has been the standard therapy.
Methods
A total of 459 women with hyperprolactinemic amenorrhea were treated with either cabergoline (0.5 to 1.0 mg twice weekly) or bromocriptine (2.5 to 5.0 mg twice daily), administered in a double-blind fashion for 8 weeks and subsequently in an open fashion for 16 weeks, during which adjustments in the dose were made according to the response. Of the 459 women, 279 had microprolactinomas, 3 had macroprolactinomas, 1 had a craniopharyngioma, 167 had idiopathic hyperprolactinemia, and the remainder had an empty sella. Clinical and biochemical status was assessed at 2-week intervals for 8 weeks and monthly thereafter for a total of 6 months, with an additional assessment at 14 weeks.
Results
Stable normoprolactinemia was achieved in 186 of the 223 women treated with cabergoline (83 percent) and 138 of the 236 women treated with bromocriptine (59 percent, P<0.001). Seventy-two percent of the women treated with cabergoline and 52 percent of those treated with bromocriptine had ovulatory cycles or became pregnant during treatment (P<0.001). Amenorrhea persisted in 7 percent of the cabergoline-treated women and 16 percent of the bromocriptine-treated women. Adverse effects were recorded in 68 percent of the women taking cabergoline and 78 percent of those taking bromocriptine (P = 0.03); 3 percent discontinued taking cabergoline, and 12 percent stopped taking bromocriptine (P<0.001) because of drug intolerance. Gastrointestinal symptoms were significantly less frequent, less severe, and shorter-lived in the women treated with cabergoline.
Conclusions
Cabergoline is more effective and better tolerated than bromocriptine in women with hyperprolactinemic amenorrhea.
Media in This Article
Figure 1
Distribution of Women with Hyperprolactinemic Amenorrhea According to the Final Dose of Bromocriptine or Cabergoline.Figure 2
Mean (±SE) Serum Prolactin Concentrations in Women with Hyperprolactinemic Amenorrhea Treated with Cabergoline or Bromocriptine.Article Activity
- Article
Dopamine-agonist drugs are the treatment of choice for most patients with hyperprolactinemia1,2. Bromocriptine has been the reference compound and effectively suppresses prolactin secretion, restores gonadal function, and shrinks prolactinomas3. It has a number of side effects, however, including nausea, dizziness, and headache, that limit the dose and may even necessitate the withdrawal of treatment4-6. Furthermore, its half-life is short so that it must be given two or three times daily.
Cabergoline is a new, selective, potent, and long-lasting dopamine agonist that inhibits prolactin secretion in both normal subjects and those with hyperprolactinemia, with a duration of action of up to 21 days after single oral doses of 0.3 to 1.0 mg7-9. In a recent multicenter study in women with hyperprolactinemia, cabergoline in doses of 0.125 to 1.0 mg twice weekly for four weeks decreased prolactin secretion in a dose-dependent fashion, and 95 percent of those receiving 1.0 mg twice weekly had normal serum prolactin concentrations10. In short-term studies8,10 and in the first reports of long-term treatment,11-13 the drug was well tolerated, and its side effects were similar to those reported with bromocriptine. We carried out this randomized, parallel-group, partially double-blind study in order to compare the effectiveness and tolerability of bromocriptine and cabergoline in women with hyperprolactinemia.
Methods
Study Design
The study was a randomized, multicenter 24-week trial comparing cabergoline (0.5 to 1.0 mg twice weekly) with bromocriptine (2.5 to 5.0 mg twice daily) in the treatment of women with hyperprolactinemic amenorrhea. The women were recruited from 67 gynecological and endocrinologic centers in Europe and Argentina. The study was approved by the institutional review board at each center, and the women gave their informed consent, either written or oral and witnessed. Treatment was given under double-blind conditions for the first eight weeks and subsequently continued on an open-label basis. The reasons for this combined design included the different dose schedules for the two drugs, which, if double-blind conditions were continued throughout the study, would have imposed a twice-daily administration schedule on the women assigned to receive cabergoline. In addition, side effects from ergot derivatives occur during the first few weeks of treatment and decline progressively thereafter. Hence, double-blind administration during the first part of the study would ensure unbiased assessment of side effects when most would be anticipated to occur. Adequate comparison of the effectiveness of the two drugs under open conditions was ensured by the objective criteria used for this purpose.
Selection of Patients
We studied 459 women 16 to 45 years of age who had had amenorrhea for at least three months and serum prolactin concentrations at least twice the upper limit of normal values for each center (Table 1Table 1
Characteristics of the Women with Hyperprolactinemic Amenorrhea Treated with Bromocriptine or Cabergoline.) on two occasions at least four weeks after the discontinuation of any previous therapy; serum prolactin concentrations of this magnitude were obtained in all but 9 of the 313 women who had been previously treated. Women who had been treated previously with either drug were not excluded unless they had had to discontinue treatment because of adverse events or had not had a 50 percent reduction in serum prolactin concentrations. Additional criteria for exclusion were the presence of a pituitary macroadenoma, any disorder that could prevent normal menstruation after the restoration of normoprolactinemia, hyperprolactinemia related to polycystic ovary disease, thyroid or adrenal disorders, renal or hepatic disease, and a history of allergy to ergot derivatives. All women had normal plasma concentrations of luteinizing hormone, follicle-stimulating hormone, and progesterone; normal tests of renal and hepatic function; normal complete blood counts; normal electrocardiograms; and negative pregnancy tests. All women underwent computed tomography or magnetic resonance imaging of the pituitary region (unless these tests had been performed within the preceding 12 months).Treatment
Each woman was centrally assigned to receive one of the study drugs in a double-blind fashion, according to computer-generated randomization lists that were stratified on the basis of country and previous therapy with either drug. During the first eight weeks the women took one tablet and one capsule (containing active drug or placebo) twice daily, with their morning and evening meals. The women assigned to the cabergoline group initially received 0.25 mg of active drug on days 1 and 5 (evening doses), and the dose was increased to 0.5 mg on the same days during weeks 2 to 8. Bromocriptine was started at a daily dose of 1.25 mg (evening dose) for three days, and the dose was increased to 2.5 mg daily for the next four days and subsequently to 2.5 mg twice daily during weeks 2 to 8. During the open-label period, dose adjustments were made, if necessary, at the end of week 8 or 16 (or both) on the basis of the serum prolactin values at the previous visit (weeks 6 and 14). The dose of bromocriptine was increased from 2.5 mg twice daily to 2.5 mg three times daily and subsequently to 5 mg twice daily; the dose of cabergoline was increased to 0.5 mg three times weekly (days 1, 3, and 5) and then to 1 mg twice weekly.
Monitoring
Serum prolactin was measured at base line and 2, 4, 6, 8, 12, 14, 16, 20, and 24 weeks after the initiation of therapy. The duration of each episode of vaginal bleeding was recorded, but only episodes lasting at least two days were considered to be menses. When menses were restored, plasma progesterone was measured during the presumed luteal phase as an indicator of ovulation. If necessary, extra visits were arranged (on day 21 of the cycle) for this purpose. Serum prolactin and plasma progesterone were measured at each center soon after the samples were obtained by different immunologic methods with the use of international standards.
At each visit the women were asked about side effects, which were classified as mild (awareness of symptoms, but easily tolerated), moderate (enough discomfort to interfere with usual activities), or severe (incapacitating, with inability to work or perform usual activities). Blood samples were collected after 4, 8, 16, and 24 weeks for blood counts and renal- and hepatic-function tests (as described above). During the double-blind period, women at risk of becoming pregnant were advised to use barrier contraception, but in the open-label period only those taking cabergoline were advised to continue such measures. A pregnancy test was performed the week before treatment was begun, at week 4, at each subsequent visit, and in any woman in whom menses had resumed but in whom a delay in menstruation was noted (beyond 32 days). Treatment was stopped if pregnancy was confirmed.
Criteria of Efficacy
The efficacy of treatment was assessed with clinical criteria (the occurrence of menses and ovulation) and biochemical measurements (serum prolactin concentrations). Complete clinical success was defined as the occurrence of at least two consecutive menses with biochemical evidence of ovulation on at least one occasion (plasma progesterone concentration above 7.9 ng per milliliter [25 nmol per liter] in samples obtained during the midluteal phase or above 3.2 ng per milliliter [10 nmol per liter] in samples not taken during the midluteal phase) or pregnancy. Partial clinical success was defined as the occurrence of two menstrual cycles without evidence of ovulation or a single ovulatory cycle. For women who did not require an adjustment in the dose, complete biochemical success was defined as a serum prolactin value within the normal range after week 6. For those whose dose was changed at week 8 or 16, biochemical success was defined as a normal serum prolactin value from week 12 or 20, respectively. Partial success was defined as a serum prolactin value above the normal range at these times, but less than 50 percent of the base-line value. Biochemical failure was defined as serum prolactin concentrations remaining above 50 percent of the base-line values.
Statistical Analysis
The null hypothesis of the superiority by 10 percent or more of bromocriptine was tested against an alternative hypothesis of a difference of less than 10 percent in favor of bromocriptine,14 which was considered to be clinically irrelevant. The clinical and biochemical success rates in the two groups were compared with Blackwelder's modified z statistics15. A complementary analysis of success rates used a logistic model including stratum (previous treatment with test drugs), treatment, and their interaction as explanatory variables16,17. The intention-to-treat approach was used in evaluating the results. The results of analysis based only on women who could be fully evaluated (i.e., those fulfilling the eligibility criteria and completing the entire treatment period with correct dose adjustments) were similar to those of the intention-to-treat analysis. The effects of the treatments on blood pressure, pulse, and hematologic and biochemical values were evaluated by descriptive statistics that included two-tailed t-tests, the median sign-rank test, and the Stuart Maxwell test. Adverse events were compared with the chi-square test; in addition, the cumulative risk and the instantaneous probability (hazard) of adverse events were estimated by life-table methods18.
Results
The women in each treatment group were comparable in terms of age, height, weight, base-line serum prolactin concentration, duration of amenorrhea, and diagnosis (Table 1). The median periods without treatment were five months in the bromocriptine group and six months in the cabergoline group. At base line 434 of the 459 women had amenorrhea; 14 women in the bromocriptine group and 11 in the cabergoline group reported vaginal bleeding in the preceding three months.
In the bromocriptine group, 214 of the 236 women (91 percent) completed eight weeks of treatment and 169 (72 percent) completed the entire treatment period. The corresponding figures for the 223 women in the cabergoline group were 211 (95 percent) and 186 (83 percent). Seven women did not start treatment (five in the bromocriptine group and two in the cabergoline group). The final drug doses are shown in Figure 1Figure 1
Distribution of Women with Hyperprolactinemic Amenorrhea According to the Final Dose of Bromocriptine or Cabergoline.. Therapy was discontinued before the end of the study in 67 women in the bromocriptine group and 37 women in the cabergoline group for the following reasons: pregnancy (12 in the bromocriptine group and 18 in the cabergoline group), drug intolerance (27 and 7, respectively), loss to follow-up (4 in each group), poor compliance with the visit schedule (6 in the bromocriptine group), and miscellaneous causes (18 in the bromocriptine group and 8 in the cabergoline group). Compliance was good in both treatment groups: none of the women in the cabergoline group and only six women in the bromocriptine group took less than 80 percent of the prescribed dose. During the open-label period, compliance with the twice-weekly schedule adopted for cabergoline was better than that with the twice-daily bromocriptine regimen (18 percent of women missed at least one dose of cabergoline, and 44 percent of women missed a dose of bromocriptine).Clinical Efficacy
Menses resumed in 191 of the 231 women (83 percent) treated with bromocriptine and in 201 of the 221 (91 percent) treated with cabergoline, usually during the first eight weeks of therapy. Regular menstrual periods (intermenstrual intervals of 21 to 35 days) were recorded in 157 women taking bromocriptine (68 percent) and 181 (82 percent) taking cabergoline. Among the women who completed the study, menses resumed in 87 percent of those taking bromocriptine and 96 percent of those taking cabergoline. When we excluded the women who became pregnant without resuming menses (3 women treated with bromocriptine and 4 treated with cabergoline) and those who were randomized but never started treatment (5 treated with bromocriptine and 2 with cabergoline), amenorrhea persisted in 37 of those taking bromocriptine (16 percent) and in 16 of the women treated with cabergoline (7 percent).
Among women whose menses resumed, plasma progesterone was measured at least once in 187 of those in the bromocriptine group (98 percent) and 191 of those in the cabergoline group (95 percent). Of these, 123 in the bromocriptine group (66 percent) and 156 in the cabergoline group (82 percent) had at least one ovulatory cycle. The proportions of women with complete or partial clinical success or failure are shown in Table 2Table 2
Comparative Efficacy of Bromocriptine and Cabergoline in Women with Hyperprolactinemic Amenorrhea.. The difference in the rates of complete success was 20 percent (95 percent confidence interval, 11 to 28 percent) and clearly indicated the superiority of cabergoline over bromocriptine. Of the 90 women in whom a clinical response could not be determined, most (the “not applicable” category in Table 2) dropped out of the study with no proved ovulation, and the remainder did not have plasma progesterone measurements. The effects of cabergoline were superior to those of bromocriptine when the rate of clinical success was analyzed according to base-line serum prolactin values (77 percent vs. 59 percent in women with pretreatment serum prolactin concentrations below 100 μg per liter and 62 percent vs. 39 percent in those with pretreatment serum prolactin concentrations of at least 100 μg per liter). Before therapy, 48 women in the cabergoline group and 45 women in the bromocriptine group had galactorrhea, which disappeared in 90 percent and 78 percent, respectively, usually within eight weeks after the start of treatment.Sixteen women treated with bromocriptine and 25 treated with cabergoline conceived, but only pregnancies in the latter group were actively monitored. There were 4 elective terminations because of unintended pregnancy, 2 early spontaneous abortions, 16 deliveries (1 cesarean and 15 vaginal), and 1 therapeutic abortion in a woman carrying an abnormal fetus (the fetus had anomalies of the legs probably related to amniotic bands); two women were lost to follow-up. All infants delivered were normal.
Biochemical Efficacy
The base-line serum prolactin concentrations were similar in the two groups (Table 1). The mean serum prolactin concentrations during the study are shown in Figure 2Figure 2
Mean (±SE) Serum Prolactin Concentrations in Women with Hyperprolactinemic Amenorrhea Treated with Cabergoline or Bromocriptine.. The mean serum prolactin concentration fell rapidly during the first two weeks of treatment in both groups. From week 4 onward, it was well within the normal range in the cabergoline group but remained slightly above normal in the bromocriptine group. The rates of complete and partial biochemical success and biochemical failure are shown in Table 2. The difference in the rate of complete success was 25 percent (95 percent confidence interval, 17 to 33 percent) in favor of cabergoline. The serum prolactin response was not adequately assessed in 67 women (the ”not applicable” category in Table 2) because they dropped out of the study or because only a single prolactin measurement was made at the final dose. In the bromocriptine group, the effective daily dose was 2.5 mg in 1 woman, 5 mg in 124, 7.5 mg in 10, and 10 mg in 3. The effective weekly cabergoline doses were 0.5 mg in 3 women, 1 mg in 167, 1.5 mg in 14, and 2 mg in 2.The differences were more pronounced in favor of cabergoline in women who had not received any previous treatment (Table 2). Cabergoline also was more effective in women with base-line serum prolactin values of either less than 100 μg per liter or 100 μg per liter or higher and in women with either microprolactinomas or idiopathic hyperprolactinemia. However, in both treatment groups the rate of complete success was higher in women with pretreatment serum prolactin concentrations below 100 μg per liter (66 percent in the bromocriptine group and 89 percent in the cabergoline group) than in those with pretreatment concentrations of 100 μg per liter or higher (43 percent in the bromocriptine group and 73 percent in the cabergoline group).
Drug Safety
With cabergoline therapy, 68 percent of the women reported adverse events, as compared with 78 percent of those taking bromocriptine (P = 0.03); during the double-blind period, the corresponding values were 63 and 71 percent, respectively (P = 0.07). The cumulative risk of adverse events during cabergoline treatment was significantly lower than during bromocriptine treatment (odds ratio, 0.6; 95 percent confidence interval, 0.4 to 1.0). In two thirds of the women who had adverse events, the events occurred within two weeks after therapy was begun; however, 15 to 20 percent of the women in each group had persistent or recurrent early symptoms or had new symptoms in subsequent weeks (Figure 3Figure 3
Percentage of Women with Hyperprolactinemic Amenorrhea Treated with Cabergoline or Bromocriptine Who Reported Adverse Effects.). Overall, adverse events (Table 3Table 3
Adverse Effects of Treatment with Bromocriptine and Cabergoline in Women with Hyperprolactinemic Amenorrhea.) were less frequent and less severe with cabergoline (14 percent vs. 20 percent, P = 0.06), and only 7 women (3 percent) had to discontinue treatment because of intolerance, as compared with 27 women (12 percent) in the bromocriptine group (P<0.001). Among the women treated with bromocriptine, nausea was significantly more frequent (P<0.001), more severe (occurring in 9 percent, as compared with 1 percent of the women treated with cabergoline; P<0.001), and of longer duration. Also, vomiting was more frequent and severe with bromocriptine than with cabergoline. Severe vomiting was reported by 5 percent of the bromocriptine-treated women but by none of the women receiving cabergoline.Test Results
Five women (two in the bromocriptine group and three in the cabergoline group) had transient increases in serum alkaline phosphatase or aminotransferase values (>100 percent above the upper limit of normal), four of whom had slightly abnormal results at base line. In two women (one in each group), the abnormality resolved only after treatment was discontinued. Approximately 50 percent of the women in each group had a drop in blood pressure (median decrease, 10 mm Hg), particularly diastolic pressure, which was symptomatic in only three women in the cabergoline group and four in the bromocriptine group. There were no electrocardiographic changes.
Discussion
These results provide clear evidence that cabergoline is more effective than bromocriptine in both normalizing serum prolactin and restoring gonadal function in women with hyperprolactinemic amenorrhea. In the doses used, cabergoline resulted in stable normoprolactinemia in a significantly higher proportion of women than did bromocriptine. The effective doses were 2.5 mg twice daily for bromocriptine and 0.5 mg twice weekly for cabergoline in approximately 90 percent of the women in whom serum prolactin concentrations became normal. The effect of cabergoline was also more rapid. As anticipated, the prolactin response was dependent on the pretreatment serum prolactin concentration; women with values below 100 μg per liter more often had normal values during treatment.
Cabergoline was also significantly more effective than bromocriptine in restoring gonadal function. The pregnancy rate cannot be interpreted as an indicator of clinical efficacy, since all women were advised to avoid conception during the double-blind period, as were those treated with cabergoline during the open-label period. The observation of only two spontaneous abortions in each group is consistent with the known rate of miscarriage in normal women.
The incidence of adverse symptoms and the number of women discontinuing treatment because of side effects were lower in the cabergoline group. The higher incidence of symptoms in previously treated women may be explained by their earlier experiences of side effects. The most frequent symptoms, typical of dopamine-agonist drugs, included nausea, headache, dizziness or vertigo, abdominal pain, weakness or fatigue, and constipation. The incidence of these symptoms was similar, except that gastrointestinal problems were less common, less severe, and shorter-lived in women treated with cabergoline. Our results are similar to those of a previous short-term, placebo-controlled trial using the same doses of cabergoline in 188 women10 and of open, uncontrolled studies of long-term therapy11-13.
The data concerning the efficacy and tolerability of bromocriptine differ from those of earlier open, uncontrolled studies that showed fewer adverse symptoms and better efficacy,3 but are in agreement with those of three recent double-blind, randomized trials comparing bromocriptine with quinagolide4-6. In two of these studies,4,6 the doses of bromocriptine and the duration of treatment were the same as in our study, whereas in the third,5 higher doses of bromocriptine (up to 20 mg daily) were allowed and a once-daily dose was used. In all, 81 women with hyperprolactinemia were studied, of whom 40 were treated with bromocriptine. Normoprolactinemia was achieved in 22 of the 40 (55 percent), and menses resumed in 22 of 28 women (78 percent) with oligomenorrhea or amenorrhea.
In conclusion, cabergoline is highly effective and well tolerated in the majority of women with hyperprolactinemic amenorrhea. It has advantages over bromocriptine in terms of both efficacy and tolerability and therefore is an important advance in the treatment of hyperprolactinemia.
Supported by Farmitalia Carlo Erba. Dr. Webster was a Medical Research Council Training Fellow in Endocrinology.
Source Information
From the Section of Endocrinology, Metabolism, and Diabetes, University of Wales College of Medicine, Cardiff, United Kingdom (J.W., I.I., M.F.S.); Pharmacia, Farmitalia Carlo Erba, Milan, Italy (G.P., A.P.); and the Endocrine Unit, Fatebenefratelli Hospital, Milan, Italy (C.I.F.).
Address reprint requests to Dr. Scanlon at the Department of Medicine, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN, Wales, United Kingdom.
Members of the Cabergoline Comparative Study Group are listed in the Appendix.
Appendix
The members of the Cabergoline Comparative Study Group are as follows: A. Chervin, H. Fideleff, C. Gurucharri, and I. Sinay, Buenos Aires, Argentina; J. Huber and S. Leodolter, Vienna, Austria; G. Tsherne, Graz, Austria; R. Abs, Antwerp, Belgium; A. Beckers and A. Stevenaert, Liege, Belgium; P.R. Koninckz, Leuven, Belgium; M. L'Hermite, Brussels, Belgium; Y. Lorcy, Rennes, France; F. Duron, J. Lubetzki, and P. Mauvais-Jarvis, Paris; P. Caron and J.P. Louvet, Toulouse, France; B. Charbonnel, Nantes, France; J.L. Codaccioni and P. Jaquet, Marseilles, France; G. Sassolas and M. Pugeat, Lyons, France; G. Schaison, Le Kremlin Bicetre, France; G. Chabrier and M. Pinget, Strasbourg, France; J. Bringer, Montpellier, France; P. Fossati, Lille, France; J. Leclere, Vandoeuvre des Nancy, France; P. Lecomte, Tours, France; P. Roger, Pessac, France; V. Rohmer, Angers, France; A.J.M. Audebert, Bordeaux, France; H. Stracke, Giessen, Germany; R. Kimmig and O.A. Muller, Munich, Germany; L. Wildt, Erlangen, Germany; G. Brabant, Hannover, Germany; M. Breckwolt, Freiburg, Germany; B. Runnebaum, Heidelberg, Germany; G. Knappe, Berlin, Germany; W. Winkelmann, Koln, Germany; P. Kaltwasser, Halle, Germany; H. Schatz, Bochum, Germany; H. Alexander, Leipzig, Germany; F. Camanni, Torino, Italy; P.G. Crosignani, A. D'Alberton, M. Muratori, and R. Fadini, Monza, Italy; C.I. Ferrari and A. Liuzzi, Milan, Italy; L. Falsetti, Brescia, Italy; M. Giusti, Genoa, Italy; M. Birkhauser, Bern, Switzerland; R.C. Gaillard, Geneva; R. Rolland, Nijmegen, the Netherlands; J. Schoemaker, Amsterdam; T. Howlett, Leicester, United Kingdom; B.A. Atkinson, Belfast, Northern Ireland; S.R. Bloom, B. Hicks, M. Katz, and S.S. Nussey, London; S. Slater, Glasgow, Scotland; M.F. Scanlon, Cardiff, Wales; M. Sheppard, Birmingham, United Kingdom; and T. Wilkin, Southampton, United Kingdom.
- References
References
1
Ho KY ,Thorner MO . Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 1988;36:67-82
CrossRef | Web of Science | Medline2
Crosignani PG ,Ferrari C . Dopaminergic treatments for hyperprolactinaemia. Baillieres Clin Obstet Gynaecol 1990;4:441-455
CrossRef | Web of Science | Medline3
Vance ML ,Evans WS ,Thorner MO . Drugs five years later: bromocriptine. Ann Intern Med 1984;100:78-91
Web of Science | Medline4
Homburg R ,West C ,Brownell J ,Jacobs HS . A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia. Clin Endocrinol (Oxf) 1990;32:565-571
CrossRef | Web of Science | Medline5
Verhelst JA ,Froud AL ,Touzel R , et al. Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study. Acta Endocrinol (Copenh) 1991;125:385-391
Medline6
van der Heijden PFM ,de Wit W ,Brownell J ,Shoemaker J ,Rolland R . CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 1991;40:111-118
CrossRef | Web of Science | Medline7
Ferrari C ,Barbieri C ,Caldara R , et al. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 1986;63:941-945
CrossRef | Web of Science | Medline8
Mattei AM ,Ferrari C ,Baroldi P , et al. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. J Clin Endocrinol Metab 1988;66:193-198
CrossRef | Web of Science | Medline9
European Multicentre Study Group for Cabergoline in Lactation Inhibition
CrossRef | Web of Science10
Webster J ,Piscitelli G ,Polli A , et al. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. Clin Endocrinol (Oxf) 1992;37:534-541
CrossRef | Web of Science | Medline11
Ferrari C ,Mattei A ,Melis GB , et al. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 1989;68:1201-1206
CrossRef | Web of Science | Medline12
Ferrari C ,Paracchi A ,Mattei AM ,de Vincentiis S ,D'Alberton A ,Crosignani PG . Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh) 1992;126:489-494
Medline13
Ciccarelli E ,Giusti M ,Miola C , et al. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 1989;69:725-728
CrossRef | Web of Science | Medline14
Blackwelder WC . “Proving the null hypothesis” in clinical trials. Control Clin Trials 1982;3:345-353
CrossRef | Medline15
Blackwelder WC ,Chang MA . Sample size graphs for “proving the null hypothesis.” Control Clin Trials 1984;5:97-105
CrossRef | Medline16
Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer, 1980. (IARC scientific publications no. 32.)
17
Cox DR, Snell EJ. The analysis of binary data. 2nd ed. London: Chapman & Hall, 1989.
18
Cutler SJ ,Ederer F . Maximum utilization of the life table method in analyzing survival. J Chronic Dis 1958;8:699-712
CrossRef | Medline
- Citing Articles (130)
Citing Articles
1
Edward R. Laws, John A. Jane, Kamal Thapar. 2012. Diagnostic considerations and surgical results for hyperfunctioning pituitary adenomas. , 692-722.
CrossRef2
Ines Donangelo, Shlomo Melmed. 2012. Pituitary Adenomas. , 739-760.
CrossRef3
Mark E. Molitch. (2011) Prolactinoma in pregnancy. Best Practice & Research Clinical Endocrinology & Metabolism 25:6, 885-896
CrossRef4
David Unuane, Herman Tournaye, Brigitte Velkeniers, Kris Poppe. (2011) Endocrine disorders & female infertility. Best Practice & Research Clinical Endocrinology & Metabolism 25:6, 861-873
CrossRef5
Alexander Bolyakov, Darius A. Paduch. (2011) Prolactin in menʼs health and disease. Current Opinion in Urology 21:6, 527-534
CrossRef6
Charlisa D. Gibson, Wahida Karmally, Donald J. McMahon, Sharon L. Wardlaw, Judith Korner. (2011) Randomized Pilot Study of Cabergoline, a Dopamine Receptor Agonist: Effects on Body Weight and Glucose Tolerance in Obese Adults. Diabetes, Obesity and Metabolismno-no
CrossRef7
Vania Santos Nunes, Regina El Dib, César Luiz Boguszewski, Célia Regina Nogueira. (2011) Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 14:3, 259-265
CrossRef8
Muriel Babey, Rahel Sahli, Istvan Vajtai, Robert H. Andres, Rolf W. Seiler. (2011) Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary 14:3, 222-230
CrossRef9
Amal Shibli-Rahhal, Janet Schlechte. (2011) Hyperprolactinemia and Infertility. Endocrinology & Metabolism Clinics of North America
CrossRef10
Alberto M. Pereira. (2011) Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. Current Opinion in Endocrinology, Diabetes and Obesity 18:4, 264-268
CrossRef11
Annamaria Colao, Silvia Savastano. (2011) Medical treatment of prolactinomas. Nature Reviews Endocrinology 7:5, 267-278
CrossRef12
Mark Sherlock, Conor Woods, Michael C. Sheppard. (2011) Medical therapy in acromegaly. Nature Reviews Endocrinology 7:5, 291-300
CrossRef13
Pallavi Iyer, Mark E. Molitch. (2011) Positive Prolactin Response to Bromocriptine in 2 Patients with Cabergoline-Resistant Prolactinomas. Endocrine Practice 17:3, e55-e58
CrossRef14
Samuel A. Pauli, Caleb B. Kallen. 2011. Endocrine Disorders and Infertility. , 90-101.
CrossRef15
W. Alexander Mann. (2011) Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach. European Journal of Clinical Investigation 41:3, 334-342
CrossRef16
Maria Menucci, Alfredo Quiñones-Hinojosa, Peter Burger, Roberto Salvatori. (2011) Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14:1, 68-74
CrossRef17
Michael C. Oh, Manish K. Aghi. (2011) Dopamine agonist–resistant prolactinomas. Journal of Neurosurgery1-11
CrossRef18
Mary P. Gillam, Mark E. Molitch. 2011. Prolactinoma. , 475-531.
CrossRef19
Graciela Stalldecker, María Susana Mallea-Gil, Mirtha Guitelman, Analía Alfieri, María Carolina Ballarino, Laura Boero, Alberto Chervin, Karina Danilowicz, Sabrina Diez, Patricia Fainstein-Day, Natalia García-Basavilbaso, Mariela Glerean, Viviana Gollan, Débora Katz, Mónica Graciela Loto, Marcos Manavela, Amelia Susana Rogozinski, Marisa Servidio, Nicolás Marcelo Vitale. (2010) Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 13:4, 345-350
CrossRef20
Esra Esim Buyukbayrak, Ayse Yasemin Karageyim Karsidag, Bulent Kars, Orhan Balcik, Meltem Pirimoglu, Orhan Unal, Cem Turan. (2010) Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia. Archives of Gynecology and Obstetrics 282:5, 561-566
CrossRef21
Lucio Vilar, Luciana Ansaneli Naves, Luiz Augusto Casulari, Monalisa Ferreira Azevedo, José Luciano Albuquerque, Fabiano Marcel Serfaty, Flavia R. Pinho Barbosa, Antonio Ribeiro Oliveira, Renan Magalhães Montenegro, Renan Magalhães Montenegro, Alberto José Santos Ramos, Manuel Santos Faria, Nina Rosa C. Musolino, Monica R. Gadelha, Cesar Luiz Boguszewski, Marcello D. Bronstein. (2010) Management of prolactinomas in Brazil: an electronic survey. Pituitary 13:3, 199-206
CrossRef22
Thomas Kitchen, Rachel Coles, Anna Smith, Piero Baglioni, Onyebuchi E. Okosieme. (2010) GIANT PROLACTINOMA IN AN ELDERLY MAN. Journal of the American Geriatrics Society 58:7, 1402-1404
CrossRef23
Donna Shoupe. 2010. Galactorrhea and Hyperprolactinemia. , 399-403.
CrossRef24
Mark E. Molitch, Alan Peaceman. 2010. Pituitary and Adrenal Disease in Pregnancy. , 335-351.
CrossRef25
Klibanski, Anne, . (2010) Prolactinomas. New England Journal of Medicine 362:13, 1219-1226
Full Text26
Lisa B. Nachtigall, Elena Valassi, Janet Lo, David McCarty, Jonathan Passeri, Beverly M. K. Biller, Karen K. Miller, Andrea Utz, Steven Grinspoon, Elizabeth A. Lawson, Anne Klibanski. (2010) Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clinical Endocrinology 72:1, 53-58
CrossRef27
Shrikrishna V. Acharya, Raju A. Gopal, Padma S. Menon, Tushar R. Bandgar, Nalini S. Shah. (2010) Giant Prolactinoma and Effectiveness of Medical Management. Endocrine Practice 16:1, 42-46
CrossRef28
Paul M. Stewart, Stephan Petersenn. (2009) 3 Rationale for treatment and therapeutic options in Cushing's disease. Best Practice & Research Clinical Endocrinology & Metabolism 23, S15-S22
CrossRef29
Shrikrishna V. Acharya, Raju A. Gopal, Tushar R. Bandgar, Shashank R. Joshi, Padma S. Menon, Nalini S. Shah. (2009) Clinical profile and long term follow up of children and adolescents with prolactinomas. Pituitary 12:3, 186-189
CrossRef30
Michael Buchfelder. (2009) Management of aggressive pituitary adenomas: current treatment strategies. Pituitary 12:3, 256-260
CrossRef31
Sanjeev Bhattacharyya, Anthony H Schapira, Dimitri P Mikhailidis, Joseph Davar. (2009) Drug-induced fibrotic valvular heart disease. The Lancet 374:9689, 577-585
CrossRef32
Chirag G. Patil, Melanie Hayden, Laurence Katznelson, Steven D. Chang. (2009) Non-surgical management of hormone-secreting pituitary tumors. Journal of Clinical Neuroscience 16:8, 985-993
CrossRef33
Sebastien Carnicella, Somayeh Ahmadiantehrani, Dao-Yao He, Carsten K. Nielsen, Selena E. Bartlett, Patricia H. Janak, Dorit Ron. (2009) Cabergoline Decreases Alcohol Drinking and Seeking Behaviors Via Glial Cell Line-Derived Neurotrophic Factor. Biological Psychiatry 66:2, 146-153
CrossRef34
Silvia S Rodriguez, Maria G Castro, Oscar A Brown, Rodolfo G Goya, Gloria M Console. (2009) Gene therapy for the treatment of pituitary tumors. Expert Review of Endocrinology & Metabolism 4:4, 359-370
CrossRef35
Jana Ježková, Václav Hána, Michal Kršek, Vladimír Weiss, Vilibald Vladyka, Roman Liščák, Josef Vymazal, Ladislav Pecen, Josef Marek. (2009) Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clinical Endocrinology 70:5, 732-741
CrossRef36
Sebastien Carnicella, Dorit Ron. (2009) GDNF — A potential target to treat addiction. Pharmacology & Therapeutics 122:1, 9-18
CrossRef37
Jana Ježková, Josef Marek. (2009) Diagnosis and treatment of prolactinomas. Expert Review of Endocrinology & Metabolism 4:2, 135-142
CrossRef38
Mimi I. Hu, Steven I. Sherman. 2009. Endocrine Complications of Head and Neck Surgery. , 85-103.
CrossRef39
Bernard Corenblum, Lauren MacKenzie. (2009) Pregnancies in Women With Dopamine Agonist-Resistant Macroprolactinomas. The Endocrinologist 19:1, 35-37
CrossRef40
Stephen F. Thung, Errol R. Norwitz. 2009. Endocrine Diseases of Pregnancy. , 615-658.
CrossRef41
Mark E. Molitch. 2009. Prolactin in Human Reproduction. , 57-78.
CrossRef42
R.E. Mansel, D.J.T. Webster, H.M. Sweetland, L.E. Hughes, K. Gower-Thomas, D.G.R. Evans, H.S. Cody. 2009. Nipple discharge. , 207-225.
CrossRef43
Mark E Molitch. 2008. The Patient with prolactinoma. , 179-190.
CrossRef44
Richard S Legro, Anuja Dokras. 2008. Achieving pregnancy in the anovulatory woman. , 215-222.
CrossRef45
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Smith, Edward R., Loeffler, Jay, Misra, Madhusmita, Pomerantz, Stuart R., Stemmer-Rachamimov, Anat, Post, Miriam D., . (2008) Case 37-2008. New England Journal of Medicine 359:22, 2367-2377
Full Text46
Giovanna Aparecida Balarini Lima, Evelyn de Oliveira Machado, Cintia Marques Santos Silva, Paulo Niemeyer Filho, Mônica Roberto Gadelha. (2008) Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline. Pituitary 11:3, 287-292
CrossRef47
Marcello D Bronstein. (2008) Long-term control of macroprolactinomas. Expert Review of Endocrinology & Metabolism 3:3, 361-376
CrossRef48
Margaret F Keil, Constantine A Stratakis. (2008) Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Review of Neurotherapeutics 8:4, 563-574
CrossRef49
Erika Cesar de Oliveira Naliato, Alice Helena Dutra Violante, Dayse Caldas, Maria Lucia Fleiuss Farias, Isabela Bussade, Adilson Lamounier Filho, Christiane Rezende Loureiro, Rosita Fontes, Yolanda Schrank, Thaissa Loures, Annamaria Colao. (2008) Bone density in women with prolactinoma treated with dopamine agonists. Pituitary 11:1, 21-28
CrossRef50
Johan A. Verhelst, Pascale J. Abrams, Roger Abs. (2008) Remission of acromegaly following long-term therapy with cabergoline: report of two cases. Pituitary 11:1, 103-107
CrossRef51
Tatiana Mancini, Felipe F. Casanueva, Andrea Giustina. (2008) Hyperprolactinemia and Prolactinomas. Endocrinology & Metabolism Clinics of North America 37:1, 67-99
CrossRef52
Annamaria Colao, Roger Abs, David González Bárcena, Philippe Chanson, Wolfgang Paulus, David L. Kleinberg. (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clinical Endocrinology 68:1, 66-71
CrossRef53
Sang Youl Rhee, Young Seol Kim. (2008) Evidence Based Medicine in Endocrinology. Journal of Korean Endocrine Society 23:6, 379
CrossRef54
Yasuhiro Kawabata, Yasushi Ueno, Fumihiko Horikawa, Hidenori Miyake, Nobuhiro Miki, Masami Ono. (2008) Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report. Surgical Neurology 69:1, 85-88
CrossRef55
Annamaria Colao, Antonella Di Sarno, Ermelinda Guerra, Rosario Pivonello, Paolo Cappabianca, Ferdinando Caranci, Andrea Elefante, Luigi M. Cavallo, Francesco Briganti, Sossio Cirillo, Gaetano Lombardi. (2007) Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clinical Endocrinology 67:3, 426-433
CrossRef56
Thomas P Smith, Lucille Kavanagh, Marie-Louise Healy, T Joseph McKenna. (2007) Technology Insight: measuring prolactin in clinical samples. Nature Clinical Practice Endocrinology & Metabolism 3:3, 279-289
CrossRef57
M Steinhoff, H Rochlitz, G Nußbaum, J Georgieva, CC Zouboulis. (2007) Reduced growth of beard as the only diagnostic sign in a patient with macroprolactinoma. Journal of the European Academy of Dermatology and Venereology 21:1, 124-126
CrossRef58
Malgorzata Brzozowska, Paul J. Roach. (2006) Timing and Potential Role of Diagnostic I-123 Scintigraphy in Assessing Radioiodine Breast Uptake Before Ablation in Postpartum Women With Thyroid Cancer. Clinical Nuclear Medicine 31:11, 683-687
CrossRef59
Agusta Olafsdottir, Janet Schlechte. (2006) Management of resistant prolactinomas. Nature Clinical Practice Endocrinology & Metabolism 2:10, 552-561
CrossRef60
Vincent Goffin, Philippe Touraine, Michael D Culler, Paul A Kelly. (2006) Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?. Nature Clinical Practice Endocrinology & Metabolism 2:10, 571-581
CrossRef61
Mark E Molitch. (2006) Prolactin-secreting tumors: what’s new?. Expert Review of Anticancer Therapy 6:9s, S29-S35
CrossRef62
Jennifer Hirshfeld-Cytron, Helen H Kim. (2006) Treatment of infertility in women with pituitary tumors. Expert Review of Anticancer Therapy 6:9s, S55-S62
CrossRef63
Felipe F. Casanueva, Mark E. Molitch, Janet A. Schlechte, Roger Abs, Vivien Bonert, Marcello D. Bronstein, Thierry Brue, Paolo Cappabianca, Annamaria Colao, Rudolf Fahlbusch, Hugo Fideleff, Moshe Hadani, Paul Kelly, David Kleinberg, Edward Laws, Josef Marek, Maurice Scanlon, Luis G. Sobrinho, John A.H. Wass, Andrea Giustina. (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology 65:2, 265-273
CrossRef64
Nader Pouratian, Jason Sheehan, Jay Jagannathan, Edward R. Laws, Ladislau Steiner, Mary L. Vance. (2006) Gamma Knife Radiosurgery for Medically and Surgically Refractory Prolactinomas. Neurosurgery 59:2, 255-266
CrossRef65
Ilana Shraga-Slutzky, Ilan Shimon, Ruth Weinshtein. (2006) Clinical and biochemical stabilization of Nelson’s syndrome with long-term low-dose cabergoline treatment. Pituitary 9:2, 151-154
CrossRef66
Annamaria Colao, Antonella Di Sarno, Ermelinda Guerra, Monica De Leo, Alberto Mentone, Gaetano Lombardi. (2006) Drug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nature Clinical Practice Endocrinology & Metabolism 2:4, 200-210
CrossRef67
Michele Rosa, Antonio Ciccarelli, Stefano Zarrilli, Ermelinda Guerra, Maria Gaccione, Antonella Sarno, Gaetano Lombardi, Annamaria Colao. (2006) The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clinical Endocrinology 64:3, 307-313
CrossRef68
Michael J. Frank, Randall C. O'Reilly. (2006) A mechanistic account of striatal dopamine function in human cognition: Psychopharmacological studies with cabergoline and haloperidol.. Behavioral Neuroscience 120:3, 497-517
CrossRef69
George Kontogeorgos, Eva Horvath, Kalman Kovacs, Claire Coire, Ricardo V. Lloyd, Bernd W. Scheithauer, Harley S. Smyth. (2006) Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Acta Neuropathologica 111:1, 46-52
CrossRef70
Marie-Louise Healy, Thomas P Smith, TJ McKenna. (2006) Diagnosis, misdiagnosis and management of hyperprolactinemia. Expert Review of Endocrinology & Metabolism 1:1, 123-132
CrossRef71
J TODD. (2005) Prolactin disorders. Medicine 33:11, 16-17
CrossRef72
Katarina Berinder, Ingela Stackenas, Olof Akre, Angelica Linden Hirschberg, Anna-Lena Hulting. (2005) Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up. Clinical Endocrinology 63:4, 450-455
CrossRef73
M. Biswas, J. Smith, D. Jadon, P. McEwan, D. A. Rees, L. M. Evans, M. F. Scanlon, J. S. Davies. (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clinical Endocrinology 63:1, 26-31
CrossRef74
Jay Jagannathan, Aaron S. Dumont, John A. Jane, Edward R. Laws. (2005) Pediatric sellar tumors: diagnostic procedures and management. Neurosurgical FOCUS 18:6, 1-5
CrossRef75
Steven Shoptaw, Donnie W. Watson, Chris Reiber, Richard A. Rawson, Margaret A. Montgomery, Maria D. Majewska, Walter Ling. (2005) Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction 100, 78-90
CrossRef76
Mark E. Molitch. (2005) Pharmacologic Resistance in Prolactinoma Patients. Pituitary 8:1, 43-52
CrossRef77
D. Kojo Hamilton, Mary Lee Vance, Paul T. Boulos, Edward R. Laws. (2005) Surgical Outcomes in Hyporesponsive Prolactinomas: Analysis of patients with Resistance or Intolerance to Dopamine Agonists. Pituitary 8:1, 53-60
CrossRef78
N FOYOUZI, Y FRISBAK, E NORWITZ. (2004) Pituitary gland and pregnancy. Obstetrics and Gynecology Clinics of North America 31:4, 873-892
CrossRef79
Julian RE Davis. (2004) Prolactin and reproductive medicine. Current Opinion in Obstetrics and Gynecology 16:4, 331-337
CrossRef80
M.P. de Miguel Novoa, A. Duran Rodríguez-Hervada, J.A. Díaz Pérez, I. Runkle de la Vega. (2004) Aspectos farmacológicos de la patología hipofisaria. Medicine - Programa de Formación Médica Continuada Acreditado 9:13, 791-797
CrossRef81
Avraham Ishay, Pierre Levahar, Ghali Qupty. (2004) Expansion of Intratumoral Hemorrhage in a Patient With Macroprolactinoma Treated With Cabergoline. The Endocrinologist 14:3, 126-128
CrossRef82
James K. Liu, William T. Couldwell. (2004) Contemporary management of prolactinomas. Neurosurgical FOCUS 16:4, 1-11
CrossRef83
Colao, Annamaria, Di Sarno, Antonella, Cappabianca, Paolo, Di Somma, Carolina, Pivonello, Rosario, Lombardi, Gaetano, . (2003) Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia. New England Journal of Medicine 349:21, 2023-2033
Full Text84
Schlechte, Janet A., . (2003) Prolactinoma. New England Journal of Medicine 349:21, 2035-2041
Full Text85
Pamela U Freda. (2003) How effective are current therapies for acromegaly?. Growth Hormone & IGF Research 13, S144-S151
CrossRef86
Giovanni Vitale, Antonella Di Sarno, Francesca Rota, Gaetano Lombardi, Annamaria Colao. (2003) When can we stop cabergoline treatment in prolactinomas?. Current Opinion in Endocrinology & Diabetes 10:4, 259-264
CrossRef87
Mark E. Molitch. (2003) Pituitary tumors and pregnancy. Growth Hormone & IGF Research 13, S38-S44
CrossRef88
A. Beckers, D. Betea, H. Valdes Socin, A. Stevenaert. (2003) The treatment of sporadic versus MEN1-related pituitary adenomas. Journal of Internal Medicine 253:6, 599-605
CrossRef89
John A. Jane, Mary Lee Vance, C. J. Woodburn, Edward R. Laws. (2003) Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach. Neurosurgical FOCUS 14:5, 1-5
CrossRef90
G ADAMSON. (2003) Subfertility: causes, treatment and outcome. Best Practice & Research Clinical Obstetrics & Gynaecology 17:2, 169-185
CrossRef91
S. Mehmet, J. K. Powrie. (2003) A survey of dopamine agonist withdrawal policy in UK endocrinologists treating patients with prolactinomas. Clinical Endocrinology 58:1, 111-113
CrossRef92
Johan Verhelst, Roger Abs. (2003) Hyperprolactinemia. Treatments in Endocrinology 2:1, 23-32
CrossRef93
Gary S. Wand. (2003) Diagnosis and Management of Hyperprolactinemia. The Endocrinologist 13:1, 52-57
CrossRef94
M VANCE. (2003) Medical treatment of functional pituitary tumors. Neurosurgery Clinics of North America 14:1, 81-87
CrossRef95
Elena Ricci, Fabio Parazzini, Tiziano Motta, Carlo I Ferrari, Annamaria Colao, Antonio Clavenna, Francesca Rocchi, Emanuela Gangi, Sandra Paracchi, Maurizio Gasperi, Maurizio Lavezzari, Anna Elisa Nicolosi, Simona Ferrero, Maria Luisa Landi, Paolo Beck-Peccoz, Maurizio Bonati. (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reproductive Toxicology 16:6, 791-793
CrossRef96
Arun P. Amar, William T. Couldwell, Joseph C. T. Chen, Martin H. Weiss. (2002) Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. Journal of Neurosurgery 97:2, 307-314
CrossRef97
Grant T. Liu. (2002) Pituitary adenomas. Current Treatment Options in Neurology 4:4, 261-269
CrossRef98
Mary Lee Vance. (2002) Resistant Prolactinomas. The Endocrinologist 12:4, 357-361
CrossRef99
Annamaria Colao, Carolina di Somma, Gaetano Lombardi, Rosario Pivonello, Antonella di Sarno. (2002) Dopamine receptor agonists for treating prolactinomas. Expert Opinion on Investigational Drugs 11:6, 787-800
CrossRef100
Paul L. Penar, David J. Nathan, Muriel H. Nathan, Afshin Salsali. (2002) Pituitary tumor diagnosis and treatment. Current Neurology and Neuroscience Reports 2:3, 236-245
CrossRef101
Stephen S Falkenberry. (2002) Nipple discharge. Obstetrics and Gynecology Clinics of North America 29:1, 21-29
CrossRef102
John S Bevan. (2001) Prolactin Disorders. Medicine 29:11, 10-14
CrossRef103
Makoto Moro, Ryuzo Torii, Hajime Ishii, Yoshikuni Tanioka, Yoichi Inada, Masami Kojima, Hirotada Tsujii. (2001) Novel hyperprolactinemia and hyperprolactinemic anovulation model using the cynomolgus monkey (Macaca fascicularis). Primates 42:4, 375-390
CrossRef104
Makoto Moro, Yoichi Inada, Hiroshi Miyata, Hidetada Komatsu, Masami Kojima, Hirotada Tsujii. (2001) Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats. Clinical and Experimental Pharmacology and Physiology 28:8, 651-658
CrossRef105
&NA;. (2001) Drug therapy usually secondary to surgery in the treatment of pituitary adenomas. Drugs & Therapy Perspectives 17:3, 5-10
CrossRef106
J. Webster. (2000) Cabergoline and quinagolide therapy for prolactinomas. Clinical Endocrinology 53:5, 549-550
CrossRef107
L. D. George, N. Nicolau, M. F. Scanlon, J. S. Davies. (2000) Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas. Clinical Endocrinology 53:5, 595-599
CrossRef108
Harpal S. Randeva, Melanie Davis, Gordana M. Prelevic. (2000) Prolactinoma and pregnancy. BJOG: An International Journal of Obstetrics and Gynaecology 107:9, 1064-1068
CrossRef109
Antonella Di Sarno, Maria Luisa Landi, Paolo Marzullo, Carolina Di Somma, Rosario Pivonello, Gaetana Cerbone, Gaetano Lombardi, Annamaria Colao. (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology 53:1, 53-60
CrossRef110
Annamaria Colao, Gaetano Lombardi, Lucio Annunziato. (2000) Cabergoline. Expert Opinion on Pharmacotherapy 1:3, 555-574
CrossRef111
Annamaria Colao, Carolina Di Somma, Sandro Loche, Antonella Di Sarno, Michele Klain, Rosario Pivonello, Marco Pietrosante, Marco Salvatore, Gaetano Lombardi. (2000) Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clinical Endocrinology 52:3, 319-327
CrossRef112
John J. Orrego, Ariel L. Barkan. (2000) Pituitary Disorders. Drugs 59:1, 93-106
CrossRef113
Jonathan Webster. (1999) Clinical management of prolactinomas. Best Practice & Research Clinical Endocrinology & Metabolism 13:3, 395-408
CrossRef114
Jonathan M Lord, Umesh Acharya. (1999) The treatment of ovulatory disorders. The Obstetrician & Gynaecologist 1:2, 33-35
CrossRef115
Maria G Castro, J.R.E Davis, Weidong Xiong, P.R Lowenstein. (1999) Recent developments in gene therapy: applications for the treatment of pituitary tumours. Best Practice & Research Clinical Endocrinology & Metabolism 13:3, 431-449
CrossRef116
V Porciatti. (1999) Losses of hemifield contrast sensitivity in patients with pituitary adenoma and normal visual acuity and visual field. Clinical Neurophysiology 110:5, 876-886
CrossRef117
Makoto Moro, Yoichi Inada, Masami Kojima, Hiroshi Miyata, Hidetada Komatsu, Ryuzo Torii. (1999) New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline. European Journal of Pharmacology 368:1, 57-66
CrossRef118
J. Blake Tyrrell, Kathleen R. Lamborn, Lisa T. Hannegan, Carol B. Applebury, Charles B. Wilson. (1999) Transsphenoidal Microsurgical Therapy of Prolactinomas: Initial Outcomes and Long-term Results. Neurosurgery 44:2, 254-261
CrossRef119
Erol Veznedaroglu, Rocco A. Armonda, David W. Andrews. (1999) Diagnosis and therapy for pituitary tumors. Current Opinion in Oncology 11:1, 27
CrossRef120
Mark E. Molitch. (1998) Pituitary diseases in pregnancy. Seminars in Perinatology 22:6, 457-470
CrossRef121
Annamaria Colao, Gaetano Lombardi. (1998) Growth-hormone and prolactin excess. The Lancet 352:9138, 1455-1461
CrossRef122
Annamaria Colao, Lucio Annunziato, Gaetano Lombardi. (1998) Treatment of prolactinomas. Annals of Medicine 30:5, 452-459
CrossRef123
David T Baird. (1997) Amenorrhoea. The Lancet 350:9073, 275-279
CrossRef124
H. Negishi, G.P. Kumar, M. Laloraya, S.S. Koide. (1997) Neutralization of pregnancy-preventing activity of cabergoline, a dopamine agonist with progesterone. Theriogenology 48:2, 241-246
CrossRef125
(1997) Cabergoline treatment for a large macroprolactinoma throughout pregnancy. Journal of Obstetrics & Gynaecology 17:4, 375-376
CrossRef126
Richard Grondin, Paul J. Bédard. (1996) Cabergoline: A Promising Agent for the Treatment of Parkinson's Disease. CNS Drug Reviews 2:2, 214-225
CrossRef127
D.J. O'Halloran, S.M. Shalet. (1996) Radiotherapy for pituitary adenomas: An Endocrinologist's perspective. Clinical Oncology 8:2, 79-84
CrossRef128
Steven G. Soule, Howard S. Jacobs. (1995) Prolactinomas: present day management. BJOG: An International Journal of Obstetrics and Gynaecology 102:3, 178-181
CrossRef129
John S. Bevan, Jullan R.E. Davis. (1994) Cabergoline: an advance in dopaminergic therapy. Clinical Endocrinology 41:6, 709-712
CrossRef130
Serri, Omar, . (1994) Progress in the Management of Hyperprolactinemia. New England Journal of Medicine 331:14, 942-944
Full Text
